Precise intensity-modulated radiotherapy outperforms 3D-CRT in advanced lung cancer

FHS
June 27, 2024
4:59 pm

Results from a new study led by researchers at The University of Texas MD Anderson Cancer Center support standard use of the more precise intensity-modulated radiotherapy (IMRT) over the alternative 3D-conformal radiotherapy (3D-CRT) for patients with unresectable, locally advanced non-small cell lung cancer (NSCLC).

ARMGO Pharma Enrolls First Patient in Phase 2 Trial of ARM210 for the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia

Trial to investigate the safety and efficacy of ARM210 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT).

July 21, 2023

Natural polyphenol boosts mitochondrial function and muscle performance during aging

Oleuropein enhances mitochondrial calcium uptake, reversing age-related declines in muscle function and energy metabolism, with promising clinical potential.

December 2, 2024

CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech – Biotech Investments

Issuer: CureVac / Key word(s): Patent 11.07.2024 / 13:00 CET/CEST The issuer is solely responsible for the content of this announcement. CureVac Provides Update on

July 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.